Price movement over the last 24 hours
ACADIA Pharmaceuticals Inc. vs Wix.Com Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Wix.Com Ltd trades at $47.58 (market cap $2.11B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.1× Wix.Com Ltd's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| ACAD | WIX | |
|---|---|---|
Market Cap | $4.49B | $2.11B |
Sector | Health | Technology |
52-Week High | $28.06 | $184.24 |
52-Week Low | $20.06 | $40.43 |
Enterprise Value | $3.69B | $1.67B |
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
WIX trades at $50.36, up 2.05% today, amid mixed signals. The stock shows strong revenue growth, reaching $1.99B in 2025, but profitability remains inconsistent with a net margin of -1.97%. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Technical indicators are bullish overall, with RSI suggesting mild overbought conditions. Positive news includes partnerships with Elavon and Microsoft, though legal investigations pose headwinds.
Outlook: Analyst consensus is bullish with a $83.13 price target, but risks include legal scrutiny and volatile earnings. Investment opportunity lies in revenue growth and strategic partnerships, countered by profitability challenges and potential legal liabilities. Near-term performance hinges on Q2 2026 earnings and resolution of investigations.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →